Metsera, Inc. Common Stock (MTSR NASDAQ) stock market data APIs
$35.5998
1.84(5.2%)
as of September 12, 2025
Try our APIs with
free plan!
Metsera, Inc. Common Stock Financial Data Overview
Price chart is built with
Anychart
Metsera, Inc., a clinical-stage biotechnology company, develops injectable and oral nutrient stimulated hormone analog peptides to treat obesity, overweight, and related diseases. It develops MET-097i and MET-233i for the treatment of obesity and overweight; MET-233i/MET-097i; and MET-002, MET-224o, MET-067i, and MET-034i to treat disorders, such as diabetes and obesity, as well as MET-815i to reduce weight or prevents weight gain. The company was incorporated in 2022 and is based in New York, New York.
Prev. Close
35.5998
Open
37.44
High
37.6963
Low
35.2385
52 wk Range
12.3-47.4
Market Cap
4 124 M
Shares Outstanding
105 M
EPS
-0.6551
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Metsera, Inc. Common Stock (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Metsera, Inc. Common Stock data using free add-ons & libraries
Get Metsera, Inc. Common Stock Fundamental Data
Metsera, Inc. Common Stock Fundamental data includes:
- Net Revenue:
- EBITDA: -178 196 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-07-29
- EPS/Forecast: NaN
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Metsera, Inc. Common Stock News
New
Metsera, Inc. (NASDAQ:MTSR) has caught the attention of institutional investors who hold a sizeable 48% stake
Key Insights Institutions' substantial holdings in Metsera implies that they have significant influence over the company's share price The top 5 shareholders own 51% of the company Ownership research...
Metsera, Inc. (MTSR)’s MET-233i Shows 8% Weight Loss in Phase 1
In this article, we will be taking a look at the 11 Best Performing Biotech Stocks So Far in 2025. Metsera, Inc. is one of them. Metsera, Inc. (NASDAQ:MTSR), a clinical-stage biotech based in New Yor...
Metsera to Present Research Highlighting its Next-Generation Obesity Portfolio at the 61st EASD Annual Meeting
NEW YORK, Sept. 11, 2025 (GLOBE NEWSWIRE) -- Metsera, Inc. (Nasdaq: MTSR), a clinical-stage biopharmaceutical company accelerating the next generation of medicines for obesity and metabolic diseases...
Metsera to Present Research Highlighting its Next-Generation Obesity Portfolio at the 61st EASD Annual Meeting
Metsera, Inc. NEW YORK, Sept. 11, 2025 (GLOBE NEWSWIRE) -- Metsera, Inc. (Nasdaq: MTSR), a clinical-stage biopharmaceutical company accelerating the next generation of medicines for obesity and metab...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
